CHILDRENS CANCER GROUP

儿童癌症组

• 批准号: 2009150
• 负责人: Leonard Stanley Sender
• 金额: $ 5.45万
• 依托单位: CHILDREN'S HOSPITAL OF ORANGE COUNTY
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-04-25 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2009150
• 关键词: 6 thiopurine; Burkitt's lymphoma; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytokine; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hematopoiesis; hematopoietic stem cells; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 12; interleukin 15; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tissue resource /registry; topotecan; trimetrexate; vincristine

Children's Hospital of Orange County (CHOC) was only recently approved as a full member institution (April 1993) in Childrens Cancer Group (CCG). Despite being a full member for only eighteen months, CHOC investigators have contributed significantly to the development of new therapeutic protocols, the establishment of two reference laboratories, and have provided significant scientific and administrative leadership within CCG. CHOC currently registers all eligible patients on to CCG protocols and is an approved CCG phase I and Bone Marrow Transplant institution. The long- term objective of this proposal is to further the improvement in the prevention, diagnosis, and treatment of childhood cancer through participation in CCG. The specific aims of this proposal include: l) providing leadership in several strategy groups, discipline committees, and study committees; 2) expanding the reference laboratories for lymphoma studies and hematopoiesis/cytokine translational research; 3) providing leadership and implementation of group phase I trials; and 4) developing pilot studies that can be translated and implemented into groupwide studies. There are presently 7 investigators at CHOC participating in 32 committee appointments. The recruitment of additional CHOC investigators will provide additional scientific and administrative CCG leadership at the level of the strategy group, study chair, study vice chair, and within scientific and discipline committees. The CHOC Hematopoisis/Cytokine Laboratory will continue to investigate stem cell regulation and cytokine receptor modulation, develop methods for ex vivo isolation and expansion of stem cells (CD34), and optimize the mobilization of peripheral stem cells for repetitive submyeloablative therapy. The Lymphoma Reference Laboratory will continue to investigate the oncogenesis of childhood lymphomas and develop alternative treatment strategies, including antisense gene therapy for Burkitt's lymphoma. Pilot phase I trials in biotherapy, immunotherapy, and hematopoiesis, including lL-2 and activated leukocytes, IL-12 + IL-15 immunotherapy, auto-graft-vs-host tumor induction, and the use of new cytokines, including thrombopoietin, will be explored at CHOC and will potentially lead to groupwide studies. In summary, CHOC will continue to provide leadership for pilot studies through CCG, participate in all open CCG phase I, II, III, and bone marrow transplant studies, develop protocols for determining the long-term effects of chemo-radiotherapy and immunotherapy, and conduct specific biological investigations in the areas of experimental hematopoiesis and childhood lymphoma.

橙子县儿童医院（CHOC）最近才被批准为 儿童癌症小组的正式成员机构（1993年4月） 尽管成为正式成员只有18个月，CHOC调查人员 为开发新的治疗方法做出了重大贡献， 议定书，建立两个参考实验室， 在CCG内部提供了重要的科学和行政领导。 CHOC目前将所有符合条件的患者登记到CCG方案中， 经批准的CCG I期和骨髓移植机构。很长的- 这项建议的长期目标是进一步改善 预防、诊断和治疗儿童癌症， 参与CCG。该提案的具体目标包括： 在多个战略小组、纪律委员会、 2）扩大参考实验室， 淋巴瘤研究和造血/细胞因子转化研究; 3） 领导和实施I期分组试验;以及4） 开展试点研究，这些研究可以转化为 集团研究。目前CHOC有7名研究人员 参加32个委员会的任命。征聘更多 CHOC研究者将提供额外的科学和管理 CCG在战略小组、研究主席、研究 副主席，并在科学和学科委员会。 CHOC 造血/细胞因子实验室将继续研究干细胞 调节和细胞因子受体调节，开发用于离体 分离和扩增干细胞（CD 34），并优化 动员外周干细胞用于重复性清髓性亚骨髓清除 疗法淋巴瘤参考实验室将继续调查 儿童淋巴瘤发生和发展替代治疗 策略，包括伯基特淋巴瘤的反义基因治疗。 生物治疗、免疫治疗和造血的I期试验， 包括IL-2和活化的白细胞，IL-12 + IL-15免疫疗法， 自体移植物抗宿主肿瘤诱导，以及新细胞因子的使用， 包括血小板生成素，将在CHOC进行探索， 导致整个集团的研究。总之，CHOC将继续提供 通过CCG领导试点研究，参与所有开放的CCG I、II、III期和骨髓移植研究，制定方案 用于确定放化疗的长期效果， 免疫疗法，并进行特定的生物学研究， 实验性造血和儿童淋巴瘤领域。